Urology Times

The ModernMedicine Network is a comprehensive platform that unites news, resources, tools, and educational programs from reliable and respected sources. It is curated by a team of experts, including advisors, consultants, influential voices, and content partners. ModernMedicine serves as a central news source for professionals in the healthcare industry.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#351494

United States

#124390

Health/Medicine

#1040

Traffic sources

Monthly visitors

Articles

App shows promise in managing lower urinary tract symptoms

1 week ago | urologytimes.com | Christian Gratzke |Benjamin P. Saylor

A recent study published in NEJM Evidence investigated the impact of conservative management, specifically an app-based therapeutic, on lower urinary tract symptoms (LUTS) in men.1 The 12-week randomized controlled trial involved over 200 men with LUTS, who were randomly assigned to an intervention group using the app in addition to their usual medication, or control group maintaining their regular medication.
“Go big or go small”: Current and emerging tools in kidney stone management

1 week ago | urologytimes.com | Brian Stork |Hannah Clarke

It’s an exciting time for stone disease, according to Brian R. Stork, MD. In a recent interview with Urology Times®, Stork offered his thoughts on recent advancements in the field and outlined potential opportunities for further development. He explained that although efforts to elucidate the causes of kidney stone formation remain ongoing, several new treatment modalities have emerged in recent years to improve the management of this condition.
Minimal approach to WVTT linked to favorable post-operative outcomes

1 week ago | urologytimes.com | Hannah Clarke

A minimal approach to water vapor thermal therapy (WVTT) involving 1 treatment per prostate lobe was associated with decreased post-operative complications in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), according to study findings published in Urology.1 The study also found that International Prostate Symptom Score (IPSS), maximum flow rate, and surgical retreatment rates were comparable when comparing the minimal approach (1 per lobe) to a...
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM

1 week ago | urologytimes.com | Ekene Enemchukwu |Hannah Clarke

Vaginal estrogen may be underutilized among female Medicare beneficiaries with genitourinary syndrome of menopause (GSM)-related conditions, according to findings from a recent study.
How rBCG EAP could open up access for Anktiva in bladder cancer

1 week ago | urologytimes.com | Suzanne Merrill |Benjamin P. Saylor

ImmunityBio has been awarded patents for the combination of BCG plus nogapendekin alfa inbakicept (Anktiva) in bladder cancer. In a recent interview with Urology Times®, Suzanne B. Merrill, MD, FACS, was asked how she foresees the integration of this combination therapy, alongside the availability of recombinant BCG, influencing future treatment paradigms for non–muscle invasive bladder cancer.
FDA clears stapler for use with da Vinci SP surgical system

2 weeks ago | urologytimes.com | Hannah Clarke

Today, April 10, 2025, the FDA granted 510(k) clearance to the SureForm 45 stapler for use with the da Vinci SP surgical system in urologic, thoracic, and colorectal procedures, Intuitive Surgical announced in a news release.1This approval marks the first clearance of a stapler designed for single-port robotic surgery in the US.
Polygenic risk score may identify more clinically significant PCa than PSA, MRI

2 weeks ago | urologytimes.com | Hannah Clarke

The use of a polygenic risk score to select patients to undergo prostate cancer screening may identify more patients with clinically significant disease than use of prostate-specific antigen (PSA) or MRI, according to data from the BARCODE1 trial (NCT03857477) published in the New England Journal of Medicine.1 “With this test, it could be possible to turn the tide on prostate cancer,” said Professor Ros Eeles, of The Institute of Cancer Research, London, in a news release on the findings.2...
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC

2 weeks ago | urologytimes.com | Neeraj Agarwal |Hannah Clarke

Data from the phase 3 TALAPRO-2 trial (NCT03395197) showed that the combination of enzalutamide (Xtandi) plus talazoparib (Talzenna) led to a statistically significant and clinically meaningful improvement in overall survival (OS) vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).1These data were recently presented at the 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium in San Francisco, California.
Label change for testosterone: Implications for urologists, prescribers, and patients

2 weeks ago | urologytimes.com | Hannah Clarke

In February 2025, the labeling requirements for testosterone caught up with what urologists and other prescribers have known for years: testosterone does not increase the risk of adverse cardiovascular outcomes.1 The journey to this conclusion began in 2014, when the FDA first convened a Joint Meeting of the Bone, Reproductive and Urologic Drugs and the Drug Safety and Risk Management Advisory Committee to discuss increased reports of stroke, heart attack, and death in men who were taking...
Ian Metzler, MD, on the increasing prevalence of kidney stones in women

2 weeks ago | urologytimes.com | Ian S. Metzler |Hannah Clarke

The prevalence of kidney stones has been increasing among women over the past decade, slowly narrowing the gap between men and women in the burden of stone disease.